Life-threatening coagulopathy and hypofibrinogenaemia induced by tigecycline in a patient with advanced liver cirrhosis

被引：72

作者：

Rossitto, Giacomo ^{[1
]}

Piano, Salvatore ^{[1
]}

Rosi, Silvia ^{[1
]}

Simioni, Paolo ^{[2
]}

Angeli, Paolo ^{[1
,3
]}

机构：

[1] Univ Padua, Dept Med DIMED, I-35100 Padua, Italy

[2] Univ Padua, Dept Cardiol Thorac & Vasc Sci, I-35100 Padua, Italy

[3] Univ Padua, Unit Hepat Emergencies & Liver Transplantat, I-35100 Padua, Italy

来源：

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY | 2014年 / 26卷 / 06期

关键词：

bacterial infection; tigecycline; liver cirrhosis; coagulopathy; bleeding; DISEASE;

D O I：

10.1097/MEG.0000000000000087

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Bacterial infections because of multidrug-resistant (MDR) bacteria are spreading worldwide. In patients with advanced liver cirrhosis, healthcare-acquired and hospital-acquired infections are common and are frequently sustained by MDR bacteria. In these settings, tigecycline, a new antibiotic, has been shown to be useful in the treatment of MDR bacteria, and it has been proposed for the treatment of hospital-acquired infections in patients with cirrhosis. Nevertheless, poor data exist on the safety profile of tigecycline in patients with cirrhosis. Here, an experience is reported in a female patient with advanced liver cirrhosis, who developed sepsis by an MDR Stenotrophomonas maltophilia and was treated with tigecycline. She experienced life-threatening side effects consisting of severe coagulopathy with hypofibrinogenaemia and subsequent gastrointestinal haemorrhage. The side effect disappeared after the withdrawal of tigecycline. Therefore, a strict monitoring of coagulation parameters in patients with cirrhosis treated with tigecycline is recommended.

引用

页码：681 / 684

页数：4

共 10 条

[1]

EUCAST (European Committee on Antimicrobial Susceptibility Testing), STEN MALT GUID DOC S

[2]

Fernández J, 2012, J HEPATOL, V56, pS1, DOI 10.1016/S0168-8278(12)60002-6

[3] Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis [J].